PREVIEW — Synthos Deep Dive v2 template · not published · founder review · 2026-07-03
Madrigal Pharmaceuticals MDGL
Healthcare · Biotechnology · Synthos Deep Dive · 2026-07-03
$529.48
Watch
Risk 8Growth 6Exponential 7Fair value $610 $260–$900
The 20-second read
What it does
Madrigal Pharmaceuticals (Nasdaq: MDGL) is a commercial-stage biopharmaceutical company focused on liver and cardiometabolic disease. Its franchise is Rezdiffra (resmetirom) — a liver-targeted, selective thyroid hormone receptor-β agonist and the first FDA-approved therapy for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) with moderate-to-advanced fibrosis.
Where it stands
$529.48 · Watch · fair value ~$610 (+15% vs price) · Risk 8/10, Growth 6/10
Where it's going
A one-drug MASH launch priced at ~11× sales — it gets interesting below ~$470 (200-DMA zone, ~25% margin of safety to our base case); a second sequential revenue decline or visible GLP-1 share loss breaks the thesis.
7/10 · High — Street models revenue ~5× to $5.1B by 2030 from a $12.2B cap, but the growth rate is decelerating, not accelerating
Technicals
Stretched — $529 above the 50-DMA ($509) and 200-DMA ($498), RSI 73 (overbought), −12% off the 52-wk high ($603), +76% 12-mo (SPY +21%) but −3% 3-mo / −9% 6-mo
Conviction
None — 0 KB claims, 0 voices. Fundamentals-driven note on a screen-surfaced name; treat accordingly
Position sizing
None yet — Watch. If triggered (~$470 or a clean Q2 print), satellite-only, ~0.5–1.5%
GLP-1s and next-wave MASH entrants flattening the Rezdiffra launch curve — Q1 2026 already printed the first sequential revenue decline (−3% QoQ)
One-line thesis. Madrigal owns the first approved MASH (fatty-liver) therapy and turned it into $958M of FY25 revenue at a 93% gross margin — a genuinely rare launch — but at ~11× sales the market is paying up for a one-molecule company that still burns ~$190M a year, just printed its first sequential revenue dip (Q1 2026: $311M vs $321M in Q4), and faces the GLP-1 class moving into its indication; with the stock overbought (RSI 73) and our base case only ~15% above the price, this is a Watch, not a buy — the trigger is ~$470 or a clean, reaccelerating Q2 print on 2026-08-04.
◆ Synthos call — WatchA one-drug MASH launch priced at ~11× sales — it gets interesting below ~$470 (200-DMA zone, ~25% margin of safety to our base case); a second sequential revenue decline or visible GLP-1 share loss breaks the thesis.
Downside Risk (lower = safer)
8/10 · Very High
Single-commercial-asset biotech burning ~$190M/yr of FCF at 10.9× EV/sales with GLP-1 competition inbound and a −$2.1B retained deficit; $984M of cash & investments and a 3.5× current ratio are the only brakes. The printed beta of −1.06 is a data artifact, not a hedge.
Growth Quality
6/10 · High
Revenue +432% in FY25 on a 93% gross margin, but the company is still −27% net margin, ROE −50%, one product, and FY27E is the first profitable year — on just 8 analysts' numbers.
Exponential Potential
7/10 · High
Street sees revenue ~5× to $5.1B and EPS $64.89 by 2030 from a $12.2B cap — genuine room to run — but growth is decelerating (+55% → +26% by FY30E), not accelerating, and it is a one-molecule bet.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Madrigal sells Rezdiffra (resmetirom), the first medicine ever approved in the U.S. for MASH — a serious fatty-liver disease that can scar the liver and previously had no approved drug at all. Being first into a big untreated disease is why sales exploded from nothing to almost a billion dollars in about two years.
The catch comes in three parts. First, this is a one-product company — if anything slows Rezdiffra, there is no second act on the market. Second, the competition is coming: the wildly popular weight-loss drug class (GLP-1s) is moving into the same disease, and those drugs treat the obesity that causes MASH in the first place. Third, the price already assumes success: you're paying about eleven times sales for a company that still loses money, and last quarter sales actually dipped slightly from the quarter before — the first wobble in the launch.
Here's what our three scores mean in everyday terms:
Downside Risk 8/10 (high). Cash in the bank is solid (~$984M), but one product, ongoing losses, a rich price tag, and new competitors is a fragile combination — if the story cracks, the fall is steep.
Growth Quality 6/10 (decent, unproven). The growth is spectacular and the margins on each pill are excellent, but the company hasn't yet shown it can turn that into actual profit — analysts think that happens next year.
Exponential Potential 7/10 (high). If the launch keeps climbing the way Wall Street models it, sales could grow five-fold by 2030 and the stock has real room. But growth is slowing down each year, not speeding up.
The one big worry: a slowing launch. Sales dipped quarter-over-quarter for the first time. If that happens again in August, the "five-fold by 2030" math the price depends on starts to look like a story, and an expensive one.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = MDGL · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$529.48
Market cap$12B
P/E trailing-50×
P/E FY26E / FY27E-73× / 53×
EV / Sales10.9×
EV / EBITDA-43.8×
Gross margin93.1%
Net margin-27.3%
Dividend yield0.00%
Beta-1.056
52-wk range$288 – $603
RSI(14)73
50 / 200-DMA$509 / $498
12-mo return+76% (SPY +21%)
Street target$669 ($542–$964)
Analyst grades20 Buy · 2 Hold · 1 Sell
FMP ratingC
Next earnings2026-08-05
What the experts actually said 0 traceable claims on MDGL · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Madrigal Pharmaceuticals (Nasdaq: MDGL) is a commercial-stage biopharmaceutical company focused on liver and cardiometabolic disease. Its franchise is Rezdiffra (resmetirom) — a liver-targeted, selective thyroid hormone receptor-β agonist and the first FDA-approved therapy for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) with moderate-to-advanced fibrosis. Headquartered in West Conshohocken, PA; CEO William J. Sibold; 528 employees — a deliberately lean commercial organization for a ~$1B-revenue drug. IPO lineage dates to 2007 (via reverse merger). Data caveat: the FMP profile text still describes Madrigal as "clinical development phase" — that is stale; the income statement shows a commercial company with $958M of FY25 product revenue.
Revenue mix — there is no mix. The FY25 segment disclosure shows a single reportable segment: $958.4M. Geographic segmentation is empty in the data file (the launch is U.S.-led; ex-U.S. expansion is a forward story we cannot quantify from this file). This is the cleanest possible illustration of the core risk: one drug, one indication, effectively one market. The pipeline behind it (per the profile, a backup compound and the legacy Roche collaboration) generates no disclosed revenue; the R&D line — $388.5M in FY25, up 64% YoY, and $108.7M in Q1 2026 alone (+146% YoY) — says management is spending heavily to build what comes next (combinations, earlier-stage fibrosis, lifecycle work), but nothing in this data file lets us underwrite it.
2. The expert thesis — why the panel is bullish (traceable)
No expert-panel coverage — this note is fundamentals-driven. A search of the Synthos knowledge base returns zero traceable claims on MDGL across all voices. There is no Visser, no ecosystem endorsement, no management transcript in the KB — nothing to cite, so nothing is cited. That is the honest house standard for a screen-surfaced name: this company entered coverage via the quant momentum screen, not via conviction voices.
What that means practically:
Conviction rating: None. The verdict below rests entirely on the FMP fundamentals, analyst estimates, and technicals in the data file — a thinner evidentiary base than a panel-backed name, and the sizing guidance in §12 reflects that.
No independent bear thesis either. The bear case in §3 is constructed from the fundamentals (launch-curve math, competitive logic, burn rate), not from a countervailing expert.
Street coverage exists and is heavily bullish (20 Buy / 2 Hold / 1 Sell, consensus target $668.83) — we show it as context, but sell-side consensus is not the Synthos conviction pool and gets zero conviction weight.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
8 · Very High
One commercial molecule, TTM FCF −$252M (firm) / burn ~$190M FY25, EV/S 10.9×, P/B 28.3×, retained deficit −$2.09B, GLP-1 competition entering the indication, and a first sequential revenue dip already in the price action. Against that: $984M cash & short-term investments, net debt only $156M, current ratio 3.5× — funded, not fragile. The printed beta of −1.06 is an artifact of idiosyncratic biotech moves, not a market hedge.
Growth Quality
6 · High
Revenue +432% FY25 ($180M → $958M) on a 93.1% TTM gross margin — elite unit economics. But net margin is −27.3%, ROE −50%, SG&A eats 81% of revenue (TTM), and the first profitable year (FY27E, EPS +$9.93) is still a forecast — from only 8 analysts. Quality is plausible, not yet demonstrated.
Exponential Potential
7 · High
Street models revenue $958M → $5.08B by 2030 (~5.3×) and EPS reaching $64.89, from a $12.2B cap — genuine multibagger room if it lands. But the growth rate decelerates every year (+55% FY26E → +50% → +36% → +33% → +26%): this is a fast S-curve, not an accelerating exponential, and it is one molecule wide.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores summarize them.
Case
Key assumptions
Fair value
Bull
Launch reaccelerates (Q1 dip proves to be copay-reset seasonality), ex-U.S. adds a leg, GLP-1s expand the diagnosed-MASH funnel rather than displace Rezdiffra; FY29E EPS ~$45 earns a ~25× growth-pharma multiple, discounted ~2.5 yrs at 9%.
~$900 (+70%)
Base(our anchor)
Consensus roughly lands — FY28E EPS $27.52 at a ~25× forward multiple ≈ $688 end-2027 value, discounted ~18 months at 9% ≈ ~$605–610; sits essentially on the Street median ($613.50).
~$610 (+15%)
Bear
The launch curve flattens: GLP-1 competition + payer friction cap revenue near the FY26 run-rate (~$1.5B), profitability slips past FY27, and the market re-rates to ~4× EV/S on a stalled story ≈ ~$260/share — just under the 52-week low ($288).
~$260 (−51%)
Synthos fair value = the base case, ~$610 (+15%), with the full $260–$900 span as the honest range. Our base sits below the Street's $668.83 consensus and on its $613.50 median — we anchored the same FY28 earnings power but applied a plainer multiple. The asymmetry is the tell: +15% to base, −51% to bear — a payoff profile that argues for waiting for either a better price or a cleaner print. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). MDGL is a high-potential S-curve, not a true accelerating exponential:
Forward growth: consensus revenue CAGR 2025→2030 of ~40%/yr ($958M → $1.49B → $2.23B → $3.03B → $4.03B → $5.08B); EPS swings from −$7.21 (FY26E) to +$9.93 (FY27E, first profit) → $27.52 → $45.14 → $64.89 (FY30E) — enormous operating leverage on a 93% gross margin once SG&A/R&D stop outgrowing sales.
Acceleration (the 2nd derivative) is negative: +432% (FY25 actual) → +55% (FY26E) → +50% → +36% → +33% → +26% (FY30E). Every year is slower than the last. That is normal launch math, but it is the opposite of the accelerating profile that earns a 9–10 here.
Room to run: $12.2B market cap against $5.1B of modeled 2030 revenue and $64.89 of modeled 2030 EPS — at even 15× that EPS the stock would roughly double. The room is real; the path is a single molecule's share of a newly contested indication.
Estimate quality caveat: the out-year numbers rest on 5 revenue / 4 EPS analysts (2029–2030) vs 11 for 2026–2028 — the far bars are sketches, not forecasts. (The FMP out-year SG&A estimate rows are internally inconsistent — SG&A above revenue — and we disregard them.)
Exponential Potential: High (7/10). Genuine multibagger geometry if the launch holds, docked for deceleration, single-asset concentration, and thin out-year coverage.
Revenue: FY25 $958.4M, +432% (FY24 $180.1M; FY23 zero — the launch began mid-2024). TTM revenue ~$1.13B.
Quarterly trajectory (the wobble): Q1'25 $137.3M → Q2 $212.8M → Q3 $287.3M → Q4 $321.1M → Q1'26 $311.3M. That is +127% YoY but −3.0% sequentially — the first QoQ decline of the launch. U.S. pharma Q1s often dip on copay resets and channel destocking (context, not from the file), but for a stock priced on the launch curve, this is the number to watch on 2026-08-04. Q1'26 revenue did beat the Street's $301.1M estimate.
Margins: gross 93.1% TTM — pharma-grade unit economics. But operating margin is −27.7% TTM: FY25 operating loss −$300.1M (R&D $388.5M + SG&A $813.8M against $902M gross profit). The loss is narrowing per quarter in relative terms (Q4'25 −$59.6M op loss on $321M revenue; Q1'26 −$92.7M, wider again on the R&D step-up to $108.7M).
Earnings: FY25 net −$288.3M, EPS −$12.85 (improved from FY24's −$21.90). Q1'26 net −$94.4M, EPS −$3.25 — a beat vs the −$3.61 estimate. The company has beaten the EPS estimate in 3 of the last 4 prints (the miss: Q3'25, −$5.08 vs −$2.04 est, on the R&D/SG&A ramp).
Cash flow: FY25 operating CF −$189.6M, capex trivial (−$0.5M), FCF −$190.0M — less than half FY24's −$457M burn. Stock comp $98.1M FY25 (~7.5% of TTM revenue). Income quality 0.87.
Balance sheet: cash + short-term investments $983.6M vs total debt $354.4M (net debt $155.7M) — FY25 added $217.9M of new debt and $38.1M of equity issuance. Current ratio 3.5×, working capital $844M. At the FY25 burn rate (~$190M), the balance sheet funds 4–5 years — the launch, not financing, is the binding risk. Retained deficit −$2.09B; equity $602.7M against a $12.2B cap explains the 28.3× P/B.
Share-count caveat: the Q1'26 income statement reports 29.03M weighted-average shares vs 22.43M in Q4'25, yet the quote's market cap implies ~23.1M shares at $529.48 — an internal inconsistency in the data file we flag rather than resolve. Per-share figures for Q1'26 should be read with that caveat.
6. Valuation — priced in or room?
There is no trailing earnings multiple to lean on — the company loses money (TTM EPS −$10.66). What the data supports: EV/sales 10.9×, P/S 10.8×, P/B 28.3× — a premium even by commercial-biotech standards, and FMP's letter rating is a blunt C (overall 2/5; ROE, ROA, D/E, P/E, P/B all score 1/5 — only the DCF score, 5/5, likes it, which is exactly the shape of a story stock: terrible on trailing, attractive on modeled cash flows). The forward compression is the entire bull case: at $529.48, ~53× FY27E EPS ($9.93) → ~19× FY28E ($27.52) → ~12× FY29E ($45.14) → ~8× FY30E ($64.89) — the forward PEG prints 0.17. If the estimates land, today's price is cheap; if the curve flattens, there is no valuation floor above ~4× sales. Street targets (context): consensus $668.83 (+26%), high $964, low $542, median $613.50 — even the low target sits above today's price, which tells you how uniformly bullish (and therefore how crowded) the sell-side stance is. Our $610 base deliberately sits on the median, not the mean. Not a value buy; a launch-curve underwrite where the multiple is hostage to two or three quarterly prints.
7. Technicals (from the tech block)
Trend: intact but tired. $529.48 sits above the 50-DMA ($508.69) and 200-DMA ($497.60), 50 above 200 — an uptrend on paper. MACD +7.18 (positive).
Location:−12.2% off the 52-week high ($602.83) — also the max drawdown from peak — and +84.2% off the 52-week low ($287.52).
Momentum (the warning): RSI(14) 72.95 — overbought. This is a stretched short-term entry by the house playbook.
Relative strength (the tell): +76.4% over 12 months vs SPY +21.1% / QQQ +31.2% — a big winner. But the near lens has flipped: −3.2% over 3 months vs SPY +14.6%, and −9.1% over 6 months vs SPY +10.2%. The stock has been underperforming the market for six months while grinding sideways-to-up — momentum leadership has already rolled off.
Read: technicals support patience, which is what the Watch verdict asks for anyway: overbought RSI into an earnings catalyst, with fading relative strength. The 200-DMA (~$498) and the round $470–480 zone below it are the natural accumulation areas if the fundamental trigger fires.
8. Moat & competitive position
Madrigal's moat is first-mover incumbency in a newly created market: the first approved MASH therapy, a 93% gross margin, the reference brand physicians learn first, and a two-year head start building the diagnostic and prescribing infrastructure for a disease that had none. In specialty pharma, that infrastructure — payer contracts, hepatologist relationships, patient identification — is a real, if soft, barrier. But the moat is one molecule wide and the siege is coming: the GLP-1 class (context: now approved in MASH) attacks the cause (obesity) rather than the liver downstream, and a deep industry pipeline is targeting the same fibrosis endpoints. The bull counter — GLP-1 noise expands MASH diagnosis rates and Rezdiffra wins the add-on/intolerant population — is plausible and unproven. ROE −50% and a −27% net margin say the moat has not yet translated into economics; the 93% gross margin says it can.
Peer set (FMP-supplied, market cap): a heterogeneous mid-cap healthcare list rather than clean comps — Moderna $32B, Jazz $15B, Exelixis $14B, Baxter $12B, BioMarin $11B, Bio-Techne $11B, Abivax $9.4B, Rhythm $7.7B, Caris $5.0B, Atrium $0.2B. The most relevant competitive comparators — the GLP-1 majors and the MASH pipeline names — are not in this supplied set: a data caveat. Within the list shown, MDGL carries by far the fastest growth and one of the richest sales multiples.
9. Management, capital allocation & guidance
Capital allocation: classic launch-mode — every dollar into the ramp. FY25: R&D $388.5M (+64%), SG&A $813.8M (+87%), zero buybacks, zero dividend, funded by $217.9M of new debt plus $38.1M of equity. Raising debt at ~$1B of cash reads as runway insurance ahead of a competitive window — defensible, and cheaper than equity at these prices. Capex is negligible (asset-light: $6.4M of PP&E).
Leadership: CEO William J. Sibold — a commercial-stage operator profile consistent with the company's pivot from R&D story to launch execution. The data file contains no compensation or tenure detail; we don't editorialize beyond it.
Insider activity: the most recent Form 4s (filed 2026-06-18) are routine annual director grants — Taub, Levy, Fouse, and Daly each received 454 RSUs and 766 options struck at $499.86. No open-market buys or sells appear in the file. Neutral signal; the $499.86 strike is at least a marker of where the board's incentives are set.
Management guidance: none is captured in our data pull (no earnings-call transcript in the KB, no guidance fields in the file) — we flag the absence rather than paraphrase from memory. The earnings calendar shows the Street expects Q2 2026 revenue of ~$349.8M and EPS of −$2.75.
10. Catalysts & what to watch
Next earnings: 2026-08-04 (Q2 2026; Street EPS −$2.75, revenue ~$349.8M). This is the whole ballgame: $349.8M vs Q1's $311.3M would be +12% sequential and would retire the Q1-wobble concern; a second flat-to-down quarter validates the bear case.
Sequential prescription/revenue trajectory — the single most informative datapoint each quarter for a launch-curve valuation.
Competitive flow into MASH: GLP-1 uptake in the indication and next-wave pipeline readouts (context to monitor; not in the data file).
Ex-U.S. expansion: geographic segment data is empty today — any disclosed international revenue would be a new leg for the model.
Path-to-profitability markers: FY27E is consensus's first profitable year (EPS +$9.93); watch whether SG&A growth finally drops below revenue growth (SG&A was 81% of TTM revenue).
Financing: none needed near-term ($984M vs ~$190M burn), so any capital raise would itself be a signal.
Thesis tripwires (what would change the call): a second consecutive sequential revenue decline; SG&A still outgrowing revenue by FY26 year-end; a competitive approval/readout that visibly bends the script trajectory; or price reaching ~$470 with the launch intact (upgrade trigger).
11. Key risks
Single-asset concentration (the structural risk): one drug, one indication, one reportable segment. Anything — safety signal, label issue, competitive displacement — that hits Rezdiffra hits 100% of revenue.
Competitive erosion: the GLP-1 class entering MASH attacks the disease upstream; a deep pipeline is behind it. The bull's "market expansion" counter-thesis is unproven.
Launch-curve risk, already flickering: Q1 2026's −3% QoQ was the first sequential decline. Launch valuations die on flat quarters, not bad ones.
Valuation / de-rating: 10.9× EV/S and 28× book with no earnings floor; our bear case (−51%) is a plain multiple-on-stalled-sales exercise, not a stress fantasy.
Still unprofitable: −$288M FY25 net loss, −$190M FCF; profitability is a FY27 forecast on 8 analysts' numbers.
Estimate fragility: out-year consensus (2029–30) rests on 4–5 analysts, and parts of the FMP estimate file are internally inconsistent (out-year SG&A rows exceed revenue) — the far-out numbers deserve wide error bars.
Data-quality caveats: printed beta (−1.06) is unusable; the Q1'26 share count conflicts with the quoted market cap; the profile description is stale. All flagged in §5 and Provenance.
No expert-panel underwriting: zero KB voices means no independent conviction check on our fundamental read — a reason for conservatism in itself.
12. Verdict, position sizing & monitoring
Watch. Madrigal is a genuinely rare asset — the first approved therapy in a large, previously untreated disease, scaling from zero to a ~$1.3B annualized run-rate in under two years on a 93% gross margin, with a funded balance sheet ($984M cash & investments vs ~$190M annual burn). If it were 30% cheaper, or if the panel had conviction voices behind it, the growth math (Street EPS of $27.52 by FY28, $64.89 by FY30) could support a tactical buy. But the setup today stacks the wrong way: a one-molecule company at ~11× sales, a first sequential revenue decline in the price action, the GLP-1 class arriving in-indication, an overbought chart (RSI 73) that has lagged the S&P for six months, only +15% to our base case against −51% to bear, and zero expert-panel coverage to lean on. We want the business; we don't want this price-and-setup combination.
Triggers to act (either): (1) price ~$470 or below (the 200-DMA zone, ~25% margin of safety to our $610 base) with the launch intact; or (2) a clean Q2 print on 2026-08-04 — revenue at/above the ~$349.8M estimate, i.e. clear sequential reacceleration — which would justify paying up on reduced launch risk.
Sizing if triggered: satellite only, ~0.5–1.5% of the flagship — sized for a single-asset biotech where a −50% gap on one bad readout is a live scenario, and sized below a panel-backed name of equal upside because conviction here is fundamentals-only.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next 2026-08-04). This verdict is logged as a tracked Synthos call as of 2026-07-06 at $529.48.
Single biggest risk: the GLP-1 wave flattening the Rezdiffra curve — a launch-priced stock with a flat launch is just an expensive loss-maker.
Provenance & disclosures
Traceability:0 KB claims, 0 voices — the Synthos knowledge base contains no MDGL coverage, so no expert thesis is cited and kb_net_conviction is null. Fabricated conviction is structurally impossible (claim-ID reconciliation); on this name there is simply nothing to reconcile. This is a fundamentals-driven note on a momentum-screen-surfaced name.
Data as-of: fundamentals 2026-03-31 (Q1 2026, filed 2026-05-06) · estimates & prices 2026-07-06 (FMP pull) · expert claims: none. Forward figures are analyst consensus (FMP), labeled as estimates; 2029–2030 rows rest on only 4–5 analysts.
Valuation assumptions (labeled): base case = FY28E consensus EPS $27.52 × 25× forward multiple, discounted ~18 months at 9% ≈ $610; bull = FY29E EPS $45.14 × 25×, discounted ~2.5 years; bear = ~4× EV/S on revenue stalled near the FY26E run-rate. Street consensus ($668.83) shown as context; we anchored to the same earnings power at a plainer multiple.
Data-quality caveats: printed beta (−1.056) is an artifact and unusable for risk math; Q1'26 weighted shares (29.0M) conflict with the market-cap-implied count (~23.1M); the FMP profile description is stale (calls the company clinical-stage); out-year SG&A estimate rows are internally inconsistent and were disregarded; geographic segment data is empty.
Peer caveat: the FMP-supplied peer list omits the relevant MASH/GLP-1 competitive set; judge against that cohort, not the heterogeneous list shown.
Industry context flag: statements about GLP-1 competition entering MASH are qualitative industry context, not sourced from the data file; no figures were attached to them.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-06. Prior versions available via the deep-dive version dropdown ("based on the info at the time").